# PANKU-Lung03: what clinicians are saying

> 34 statements from 6 sources (5 posts, 1 paper), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
- NCT ID: NCT06500026
- Registry: https://clinicaltrials.gov/study/NCT06500026
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: izalontamab brengitecan (BL-B01D1)
- Indication: recurrent small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: be14be9482f2b50bff0a9c5ac413ae081cc74f9ce5335e143b94ddbc5a271418

## Counts

- Commentary sources screened: 13
- Sources cited by verified statements: 6
- Verified statements: 34
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 12
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 4
- Speakers cited: 4
- Cited speakers with a verified identity: 4
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 4
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 4
- By role and specialty (the abstract's specialty counts):
  - 4 physician, Medical oncology
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist sees earlier iza-bren responses as suggesting benefit in PANKU-Lung03, but remains concerned about treatment-related deaths despite no observed ILD. Another medical oncologist emphasizes that hematologic toxicity was generally managed with supportive care. Direct trial commentary is limited: these safety assessments concern earlier iza-bren evidence, and the sources reviewed for this edition do not establish an advantage over topotecan.

## Question clinicians left open

What do clinicians need PANKU-Lung03 to show about objective response, overall survival and fatal treatment-related toxicity before using izalontamab brengitecan rather than topotecan for recurrent SCLC after first-line platinum-based chemotherapy plus anti-PD-(L)1 therapy?

From finding F3 (9 statements from 2 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F3. Iza-bren: why a clinician sees phase Ib response as a signal for phase III efficacy
  - 9 statements from 2 speakers in 4 sources.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 2 of the report's 4 cited clinicians.
- F4. HER3 versus EGFR: what speakers say
  - 10 statements from 2 speakers in 4 sources.
  - 2 of the report's 4 cited clinicians.

### Beyond the trial population

- F1. Phase Ib iza-bren: where clinicians split on the safety assessment
  - 7 statements from 2 speakers in 4 sources.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician.
  - 2 of the report's 4 cited clinicians.
- F2. Phase I iza-bren: clinicians highlight ORR, but one flags fatal TRAEs
  - 12 statements from 3 speakers in 5 sources.
  - 3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags fatal TRAEs”.
  - 3 of the report's 4 cited clinicians.
- F5. Other phase III ADC trials: why a clinician expects Topotecan to give way
  - 1 statement from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 4 cited clinicians.

3 of the 5 findings and 14 of the 34 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F3 | 9 | 7 | 4 | 2 | 3 |
| F4 | 10 | 6 | 4 | 2 | 3 |
| F1 | 7 | 7 | 4 | 2 | 2 |
| F2 | 12 | 9 | 5 | 3 | 3 |
| F5 | 1 | 1 | 1 | 1 | 1 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F3 | 3 | 1 | 0 | 2 | 3 | 9 | 0 | 3 posts and articles, 1 publication |
| F4 | 5 | 2 | 0 | 0 | 3 | 10 | 0 | 3 posts and articles, 1 publication |
| F1 | 4 | 0 | 0 | 0 | 3 | 8 | 0 | 3 posts and articles, 1 publication |
| F2 | 5 | 1 | 0 | 1 | 5 | 12 | 1 | 4 posts and articles, 1 publication |
| F5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Overall survival (OS): F3 (1 shared claims)
- Secondary endpoints: F3 (1 shared claims)
- Population and setting: F3 (2 shared claims)
- The comparison: F3 (3 shared claims)
- Safety and tolerability: F3 (1 shared claims)
- Design and conduct: no finding draws on it directly

## Abbreviations

- ADC: antibody–drug conjugate
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- ILD: interstitial lung disease
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- OS: overall survival
- SCLC: small cell lung cancer

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 34 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 4 of the 4 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

9 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall survival (OS) | discussed | 6 | 4 |
| Secondary endpoints | discussed | 6 | 4 |
| Population and setting | discussed | 7 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 3 | 2 |
| Safety and tolerability | discussed | 3 | 3 |
| Design and conduct | no commentary found | 0 | 0 |
| Dual-target rationale and exploratory receptor biomarkers | discussed | 3 | 3 |
| Platinum sensitivity and prior irinotecan | discussed | 1 | 1 |
| Phase III expectations drawn from earlier evidence | discussed | 4 | 3 |
| Broader ADC expectations for topotecan's role | discussed | 1 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 17 statements · 50%** | | | |
| X threads | 17 | 5 | 13 |
| **Primary sources · 17 statements · 50%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 17 | 1 | not screened |

- Screened window: 2025-05-24 to 2026-10-24
- Cited window: 2025-05-30 to 2026-09-13
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
- Registry: NCT06500026 (https://clinicaltrials.gov/study/NCT06500026)
- Study IDs: BL-B01D1-304
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 722 (actual)
- Start: 2024-08-07 (actual)
- Primary completion: 2026-12 (estimated)
- Primary endpoint: Overall survival (OS) (Up to approximately 24 months)
- Intervention: BL-B01D1 (drug)
- Intervention: Topotecan (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 50 sources about other trials or topics are not included.
- Discussion was identified mainly through the trial identifier and known drug names. Unnamed references, spelling variants and clinical-decision discussions about relapsed SCLC may therefore be missing.
- The detailed efficacy and safety material concerns the supporting NCT05194982 phase Ib study. It must not be read as NCT06500026 results or as a head-to-head comparison with topotecan.
- The reviewed accounts report different response estimates in 2025 and 2026 without explaining the differences. They do not establish why estimates differ or that any author changed their view.
- No protocol text or exact regulatory label for BL-B01D1 was available in the sources reviewed. Detailed operational requirements and licensed-use implications cannot be established here.
- Small subgroup analyses and exploratory biomarkers limit conclusions about treatment-history effects, receptor-based selection and mechanism.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 34 verified statements · 12 from 4 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (4 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/panku-lung03-nct06500026
- Agents: POST https://www.erudio.com/api/orders with {"report": "panku-lung03-nct06500026", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=panku-lung03-nct06500026

## Cite

Erudio Health. PANKU-Lung03 (NCT06500026): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/panku-lung03-nct06500026

## Questions

### How much does the PANKU-Lung03 report cost?

One edition costs $750 (Focused · 34 verified statements · 12 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the PANKU-Lung03 report cover?

34 statements from 6 sources (5 posts, 1 paper), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the PANKU-Lung03 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "panku-lung03-nct06500026" }) previews it and create_order({ "report": "panku-lung03-nct06500026", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the PANKU-Lung03 report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/panku-lung03-nct06500026.json
- Markdown: https://www.erudio.com/reports/panku-lung03-nct06500026.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/panku-lung03-nct06500026/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "panku-lung03-nct06500026"}`
